3 Horrendous Health-Care Stocks This Week: VIVUS, Inc. (VVUS), Accretive Health, Inc. (AH), Dynavax Technologies Corporation (DVAX)

Page 1 of 2

While the federal government now gets to deal with “massive” budget cuts of around 2.3% of total annual federal spending put into law by President Obama and Congress, some investors are left wishing they could be so lucky after the past week. Here are three horrendous health-care stocks for the week with losses that make the levels of sequestration cuts sound like a great deal.

VIVUS, Inc. (NASDAQ:VVUS)No help for Heplisav
Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) plunged 33% this week after the Food and Drug Administration rejected approval for hepatitis B vaccine Heplisav. This wasn’t really a huge surprise, though, since the FDA’s advisory committee recommended against approval back in November.

The roadblock relates primarily to safety of the vaccine. Dynavax announced that the FDA’s response indicated that further evaluation was needed to evaluate safety and that it had concerns that Heplisav could cause rare autoimmune diseases. The agency also needed additional information about the quality control processes for manufacturing the vaccine.

Is Dynavax Technologies Corporation (NASDAQ:DVAX) now dead in the water? Maybe not. The company stated that the FDA “indicated its willingness to continue discussions regarding a more restricted use of Heplisav.” Dynavax thinks that it might be able to move forward with a more restricted approval of the drug, perhaps limited to adults over age 40 or patients with chronic kidney disease, without addidtional clinical studies.

No hurry, much worry
Accretive Health, Inc. (NYSE:AH) announced this week that it was postponing the release of its fourth-quarter and full-year financial results. The market fretted over the delay, sending shares down 23% for the week.

The company explained the reason for the postponement was that it needed to evaluate how revenue is recognized for revenue cycle management agreements. Accretive didn’t think that total revenue would be affected, but the timing in which the revenue was recognized might be.

If adjustments aren’t too extensive, Accretive Health, Inc. (NYSE:AH) should recover over time from this week’s meltdown. You have to wonder, though, how a company that is in the business of managing revenue cycles for its customers can mess up its own revenue. Accretive’s competitors will probably raise that very question for quite a while.

Waiting for weight pill success
Investors in VIVUS, Inc. (NASDAQ:VVUS) will have to wait longer for a turnaround in the stock’s decline. Shares fell 18% this week, adding to a long slide that began last summer.

VIVUS released its fourth-quarter results on Monday. Unfortunately for its shareholders, those results weren’t too great. VIVUS, Inc. (NASDAQ:VVUS) lost $0.56 per share, worse than the consensus analyst estimates of $0.44 per share. Analysts were expecting revenue to be around $4 million, but actual revenue came in far lower at $2 million.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!